BidaskClub upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a sell rating to a hold rating in a research report sent to investors on Tuesday, September 18th.

Several other research analysts have also recently weighed in on the stock. Morgan Stanley boosted their price target on shares of GALAPAGOS NV/S from $126.00 to $127.00 and gave the company an overweight rating in a research report on Monday, August 6th. JPMorgan Chase & Co. started coverage on shares of GALAPAGOS NV/S in a research report on Wednesday, September 12th. They set an overweight rating and a $140.00 price target on the stock. Goldman Sachs Group reissued a neutral rating on shares of GALAPAGOS NV/S in a research report on Friday, August 17th. Credit Suisse Group set a $92.00 price target on shares of GALAPAGOS NV/S and gave the company a hold rating in a research report on Tuesday, August 7th. Finally, Stifel Nicolaus boosted their price target on shares of GALAPAGOS NV/S from $109.00 to $111.00 and gave the company a buy rating in a research report on Wednesday, September 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. GALAPAGOS NV/S presently has an average rating of Hold and an average target price of $114.57.

Shares of GALAPAGOS NV/S stock traded up $1.65 during trading hours on Tuesday, reaching $99.59. 73,775 shares of the company’s stock were exchanged, compared to its average volume of 111,014. The firm has a market capitalization of $5.76 billion, a price-to-earnings ratio of -37.72 and a beta of 2.00. GALAPAGOS NV/S has a 1 year low of $84.13 and a 1 year high of $122.28.

GALAPAGOS NV/S (NASDAQ:GLPG) last announced its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.91) by $0.41. The firm had revenue of $59.27 million for the quarter, compared to analysts’ expectations of $50.58 million. GALAPAGOS NV/S had a negative net margin of 70.80% and a negative return on equity of 13.26%. As a group, equities analysts expect that GALAPAGOS NV/S will post -3.12 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Federated Investors Inc. PA lifted its position in GALAPAGOS NV/S by 9.3% in the second quarter. Federated Investors Inc. PA now owns 1,424,763 shares of the biotechnology company’s stock valued at $131,335,000 after buying an additional 121,415 shares during the last quarter. Farallon Capital Management LLC lifted its position in GALAPAGOS NV/S by 6.3% in the first quarter. Farallon Capital Management LLC now owns 308,260 shares of the biotechnology company’s stock valued at $30,752,000 after buying an additional 18,260 shares during the last quarter. Peregrine Capital Management LLC lifted its position in GALAPAGOS NV/S by 5.4% in the second quarter. Peregrine Capital Management LLC now owns 107,675 shares of the biotechnology company’s stock valued at $9,925,000 after buying an additional 5,539 shares during the last quarter. Dorsey Wright & Associates lifted its position in GALAPAGOS NV/S by 9.1% in the second quarter. Dorsey Wright & Associates now owns 98,544 shares of the biotechnology company’s stock valued at $9,312,000 after buying an additional 8,186 shares during the last quarter. Finally, Alps Advisors Inc. lifted its position in shares of GALAPAGOS NV/S by 7.7% during the second quarter. Alps Advisors Inc. now owns 73,389 shares of the biotechnology company’s stock worth $6,765,000 after purchasing an additional 5,234 shares in the last quarter. 14.64% of the stock is currently owned by institutional investors.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Further Reading: How analysts view the yield curve

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.